Stocks Under Scanner in the Biotech Space -- Merrimack Pharma, MannKind, NeuroDerm, and Celsion
23 Aug, 2017, 06:50 ET
NEW YORK, August 23, 2017 /PRNewswire/ --
If you want a Stock Review on MACK, MNKD, NDRM, or CLSN then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. On Tuesday, August 22, 2017, the NASDAQ Composite ended the trading session at 6,297.48, up 1.36%; the Dow Jones Industrial Average edged 0.90% higher, to finish at 21,899.89; and the S&P 500 closed at 2,452.51, slightly advancing 0.99%. Gains were broad based as all nine sectors ended the day in positive. This Wednesday, DailyStockTracker.com has initiated reports coverage on the following Biotechnology equities: Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), MannKind Corp. (NASDAQ: MNKD), NeuroDerm Ltd (NASDAQ: NDRM), and Celsion Corp. (NASDAQ: CLSN). Take a look at the free research reports issued today on DailyStockTracker.com for these stocks by signing up at: http://dailystocktracker.com/register/
Cambridge, Massachusetts headquartered Merrimack Pharmaceuticals Inc.'s stock finished Tuesday's session 2.52% lower at $1.16 with a total trading volume of 1.12 million shares. The stock is trading below its 50-day moving average by 10.95%. Additionally, shares of Merrimack Pharma, which engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the US, have a Relative Strength Index (RSI) of 33.83. Sign up and read the free research report on MACK at: http://dailystocktracker.com/registration/?symbol=MACK
On Tuesday, shares in Valencia, California headquartered MannKind Corp. recorded a trading volume of 542,669 shares. The stock ended the session 0.71% higher at $1.42. The Company's shares have advanced 13.60% in the past month and 9.23% in the previous three months. The stock is trading above its 50-day moving average by 6.03%. Moreover, shares of MannKind, which focuses on the discovery, development, and commercialization of therapeutic products for diabetes diseases in the US, have an RSI of 57.86.
On August 11th, 2017, research firm Maxim Group initiated a 'Buy' rating on the Company's stock, with a target price of $4 per share. The complimentary research report on MNKD can be downloaded at: http://dailystocktracker.com/registration/?symbol=MNKD
Rehovot, Israel headquartered NeuroDerm Ltd's shares closed the day 0.13% lower at $38.60. The stock recorded a trading volume of 1.20 million shares, which was above its three months average of 619.86 thousand shares. The Company's shares have gained 77.47% over the previous three months, 122.61% over the last twelve months, and 73.87% since the start of the year. The stock is trading above its 50-day and 200-day moving averages by 16.07% and 49.65%, respectively. Additionally, shares of NeuroDerm, which engages in developing drug-device combinations for the treatment of central nervous system disorders, have an RSI of 74.47.
On August 02nd, 2017, research firm ROTH Capital downgraded the Company's stock rating from 'Buy' to 'Neutral'. Register for free on DailyStockTracker.com and access the latest report on NDRM at: http://dailystocktracker.com/registration/?symbol=NDRM
Shares in Lawrenceville, New Jersey headquartered Celsion Corp. finished 3.76% lower at $1.28. The stock recorded a trading volume of 164,594 shares. The stock is trading below its 50-day moving average by 33.19%. Furthermore, shares of Celsion, which focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer, have an RSI of 30.06. Get free access to your research report on CLSN at: http://dailystocktracker.com/registration/?symbol=CLSN
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://dailystocktracker.com/disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Share this article